EVALUATION OF PRIMARY EXTRANODAL NON-HODGKIN LYMPHOMA: A RECORD BASE STUDY
Dr. Bipin Gandhi
Associate Professor Department of Pathology Vedanta Institute of Medical Sciences Dahanu, Palghar, Maharashtra.

Article Info: Received 29 November 2018; Accepted 29 December. 2018
Cite this article as: Gandhi, D. B. (2019). EVALUATION OF PRIMARY EXTRANODAL NON-HODGKIN LYMPHOMA: A RECORD BASE STUDY. International Journal of Medical and Biomedical Studies, 3(2).
DOI: https://doi.org/10.32553/ijmbs.v3i2.639
Address for Correspondence: Dr. Bipin Gandhi, Associate Professor Dept. of Pathology, Vedanta Institute of Medical Sciences Dahanu, Palghar, Maharashtra.
Conflict of interest: No conflict of interest.

Abstract
INTRODUCTION: Non-Hodgkin lymphoma (NHL) is a group of lymphoproliferative, malignant disorders arising in lymph nodes having heterogeneous, histological, and clinical characteristics. The typical clinical presentation is with lymphadenopathy or an extranodal mass. Systemic ‘B’ symptoms of fever, night sweats or weight loss are present in up to one third of patients at diagnosis. Extranodal lymphoma is prognostically important in any lymphoma. Hodgkin lymphoma is usually confined to the lymph nodes. Extralymphatic extension or involvement of spleen in a case of primary nodal disease upstages the disease in group III. National cancer database report on NHL shows patient with primary extranodal disease tend to present in lower stage than the primary nodal disease.

MATERIAL AND METHODS: Tissue was processed routinely in 10% formalin and 5 μ paraffin sections were stained with hamatoxylin and eosin. Immunohistochemistry (IHC) was performed in the department of pathology using a panel of antibodies depending on the morphology. Immunohistochemical analyses were performed manually on the paraffin embedded tissue sections by using a panel of monoclonal antibodies. Primary nodal NHL with secondary extranodal involvement and plasmacytomas were also excluded from the study. All cases were classified based upon morphologic and immunophenotypic criteria according to World Health Organization (WHO) 2008 classification while Clinical stage of NHL was defined according to the Ann Arbor classification.

RESULTS: 100 NHL were diagnosed. Of them, 21 (21%) cases were Primary extranodal NHL (pENL)s. out of 21 cases 14 (67%) were male and 7(33%) were female. majority of the patients in our study were in the 5th decade of life.

CONCLUSION: Primary extranodal lymphomas shows a diversity in lymphoid malignancies. Gastrointestinal tract was the most commonest site for Primary extra nodal lymphomas while, diffuse large B-cell lymphoma was the most common histological subtype. Most common site for Extranodal NHL was Gastrointestinal tract 10 (47.6%) followed by Nasopharyns 4(19%). In kidney 3 (14.3%, Bone 2(9.5%) and 1(4.8%) each in breast and brain was diagnosed.In histological subtypes 76.2% were DLBL, 14.3% were MALTOMA, 4.8% each were BL and NK/T cell lymphoma.

Introduction:
Non-Hodgkin lymphoma (NHL) is a group of lymphoproliferative, malignant disorders arising in lymph nodes having heterogeneous, histological, and clinical characteristics. Non-Hodgkin's lymphomas (NHL) arise from a single
mutant lymphoid cell which gives rise to a malignant clone. The genetic changes which are associated with lymphomatous transformation have been extensively investigated and have contributed greatly to knowledge of tumourigenesis in general. Chromosomal abnormalities can be identified in more than 85% cases of NHL specimens. The typical clinical presentation is with lymphadenopathy or an extranodal mass. Systemic ‘B’ symptoms of fever, night sweats or weight loss are present in up to one third of patients at diagnosis.

Extranodal lymphoma is prognostically important in any lymphoma. Hodgkin lymphoma is usually confined to the lymph nodes. Extralymphatic extension or involvement of spleen in a case of primary nodal disease upstages the disease in group III. National cancer database report on NHL shows patient with primary extranodal disease tend to present in lower stage than the primary nodal disease.

Over the past few years lymphomas arising in the extra nodal sites have shown a rapid increase in incidence particularly in central nervous system, gastrointestinal tract (GIT) and the skin. This may be correlated to immunosupression due to AIDS or immunosuppressive treatments, infections such as Helicobacter pylori, Chlamydia psittaci, Borrelia burgdorferi, and Campylobacter jejuni, autoimmune disorders and environmental factors. The types of lymphoma can be encountered vary widely from one extranodal site to another. Extra nodal lymphoma is further classified as primary and secondary. Secondary lymphoma indicating that the lymphoma first presented in an extra nodal site.

Staging and accurate localization of the disease are essential for deciding the treatment outcome and prognosis. Most histopathologists in the United Kingdom and Europe have used the Kiel classification, whereas the National Cancer Institute Working Formulation has been used in the United States.

**MATERIAL AND METHODS**

Present cross-sectional study was carried out in the department of pathology at Vedanta Institute of Medical Sciences Dahanu, Palghar, Maharashtra. Tissue was processed routinely in 10% formalin and 5 μ paraffin sections were stained with hamatoxylin and eosin. Immunohistochemistry (IHC) was performed in the department of pathology using a panel of antibodies depending on the morphology. Immunohistochemical analyses were performed manually on the paraffin embedded tissue sections by using a panel of monoclonal antibodies. Primary nodal NHL with secondary extranodal involvement and plasmacytomas were also excluded from the study.

All cases were classified based upon morphologic and immunophenotypic criteria according to World Health Organization (WHO) 2008 classification while Clinical stage of NHL was defined according to the Ann Arbor classification.

**OBSERVATIONS AND RESULTS**

During the study period, 100 NHL were diagnosed. Of them, 21(21%) cases were Primary extranodal NHL (pENL)s. out of 21 cases 14 (67%) were male and 7(33%) were female. majority of the patients in our study were in the 5th decade of life.

|Site                    | N=21 | %    |
|------------------------|------|------|
|Gastrointestinal tract  | 10   | 47.6%|
|Nasophrynx              | 4    | 19.0%|
|Kidney                  | 3    | 14.3%|
|Bone                    | 2    | 9.5% |
|Brain                   | 1    | 4.8% |
|Breast                  | 1    | 4.8% |
|Total                   | 21   | 100.0%|

Most common site for Extranodal NHL was Gastrointestinal tract 10 (47.6%) followed by Nasophynx 4(19%). In kidney 3 (14.3%, Bone 2(9.5%) and 1(4.8%) each in breast and brain was diagnosed.
In 2 cases of gastric lymphoma of mucosaassociated lymphoid tissue H. pylori was detected in gastric biopsy.

Table 2: Common histological subtypes in primary extranodal lymphomas of gastrointestinal tract

| histological subtypes | N=21 | %    |
|-----------------------|------|------|
| DLBL                  | 16   | 76.2%|
| MALTOMA               | 3    | 14.3%|
| BL                    | 1    | 4.8% |
| NK/T cell             | 1    | 4.8% |

DLBL: Diffuse large B cell lymphoma, Maltoma: mucosa associated lymphoid tissue lymphoma, BL: Burkitts lymphoma, NK Natural killer cell

In histological subtypes 76.2% were DLBL, 14.3% were MALTOMA, 4.8% each were BL and NK/T cell lymphoma.

DISCUSSION

Lymphomagenerally originates in lymph nodes. Infiltration of malignant lymphomatous cells in the organs other than lymph node is termed as extranodal lymphoma. Almost any organ in the body can be affectedextranodallymphoma. The most frequently involved system is GI tract followed by Waldeyer’s ring, lung, liver, spleen, bone and and skinxv. Primary extra nodal lymphomas constitute about 24-48% of lymphomas according to the studiesxvi. Tumoursoriginating from non lymph-nodal tissue is termed as primary extranodallymphoma, whereas hematogenous spread of disease from lymph nodes to extranodal tissue is secondary extranodal lymphoma xvii.

Our study reported 21 of extranodal NHL of which 14 (67%) were male and 7(33%) were female. Majority of the patients in our study were in the 5th decade of life.

Most common site for Extranodal NHL was Gastrointestinal tract 10 (47.6%) followed by Nasophrynx 4(19%). In kidney 3 (14.3%, Bone 2(9.5%) and 1(4.8%) each in breast and brain was diagnosed. Panel of markers like , LCA, CD99, HMB45, chromogranin, vimentin, and desmin was used. In nasophrynx cases IHC with high molecular weight cytokeratin was done to exclude a nonkeratinizing undifferentiated carcinoma.

Primary breast lymphoma incidence ranges from 0.04% to 0.5% of all breast malignancies as shown in the studiesxiv. In our study it was 4.8%. This was significantly higher than other studies. Primary NHL of the brain was 2% of NHL’s and 5% of brain tumorsxv. In our study it was 4.8%.

Gastrointestinal tract was the most commonest site(47.6%). Singh et al.xvi showed extranodal lymphomas constitute 44% with the most common site being the head and neck, whereas a study conducted by Padhi et al.xvii from Southern India showed extranodal lymphomas constituted 22% and the most common site being the central nervous system.

Diffuse large B-cell lymphoma (76.2%) was the most common histological subtype in our study followed by 14.3% MALTOMA, 4.8% each BL and NK/T cell lymphoma. These results were similar to Mishra P et al.xviii

CONCLUSION

Primary extranodal lymphoma shows a diversity in lymphoid malignancies. Extra nodal lymphomas should be accurately diagnosed for treatment outcome and prognosis of the patients in our study gastrointestinal tract was the most commonest site for Primary extra nodal lymphomas while, diffuse large B-cell lymphoma was the most common histological subtype.

REFERENCES

1. Evans LS, Hancock BW. Non-Hodgkin lymphoma. Lancet 2003;362:139-46.
2. (1987) Fifth International Workshop on Chromosomes in Leukaemia-Lymphoma. Correlation of chromosome abnormalities with histologic and immunologic characteristics in non-Hodgkin’s lymphoma and adult T cell leukaemia-lymphoma Blood 70:1554–1564.
3. Yunis JJ, Frizzera G, Oken MM, McKenna J, Theologides A, Arnesen M (1987) Multiple
recurrent genomic defects in follicular lymphoma: a possible model for cancer. N Engl J Med 316:79–84.
4. (1982) The Non-Hodgkin's Lymphoma Pathological Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 9:2112–2135.
5. Glass AG, Karnell LH, Menck HR. The National Cancer Data Base report on non-Hodgkin's lymphoma. Cancer. 1997 Dec 15; 80(12):2311-20.
6. Zucca E, Cavalli F. Extranodal lymphomas. http://annonc.oxfordjournals.org/
7. Rehman SA, Sidique M, Ahmad G, Naiz M. Extra nodal lymphoma. Prof Med J 2005;12:223-9.
8. Lennert K, Mohri N, Stein H, Kaiserling E (1975) The histopathology of malignant lymphoma. Br J Haematol 31 (suppl) 193–203
9. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pilleri SA, Stein H, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4 th ed. Lyon, France: IARC; 2008.
10. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin’s disease staging classification. Cancer Res 1971;31:1860-1
11. Paes FM, Kalkanis DG, Sideras PA, Serafini AN. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease.Radiographics. 2010 Jan; 30(1):269-91.
12. Economopoulos T, Papageorgiou S, Rontogianni D, Kaloutsi V, Fountzilas G, Tsatalas C, et al. Multifocal extranodal non-Hodgkin lymphoma: A clinicopathologic study of 37 cases in Greece, a Hellenic cooperative oncology Group study. Oncologist 2005;10:734-8.
13. Even-Sapir E, Lievshitz G, Perry C, Herishanu Y, Lerman H, Metser U. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease. RadioClin North Am. 2007 Jul; 45(4):697-709, vii.
14. ignot S, Ledoussal V, Nodiot P, Bourguignat A, Janvier M, Mounier N, et al. Non-Hodgkin's lymphoma of the breast: A report of 19 cases and a review of the literature. Clin Lymphoma 2005;6:37-42.
15. Blay JY, Ongolo-Zogo P, Sebban C, Carrie C, Thiesse P, Biron P. Primary cerebral lymphomas: Unsolved issues regarding first-line treatment, follow-up, late neurological toxicity and treatment of relapses. The FNCLCC. French FédérationNationale des Centres de Luttecontre le Cancer. Ann Oncol 2000;11Suppl 1:39-44.
16. Singh D, Kumar L, Goyal H, Raina V, Bijlani L, Wadhwa J, et al. Primary extranodal non-Hodgkin’s lymphoma in Northern India. Proc Am SocClinOncol 2003;22:2457.
17. Padhi S, Paul TR, Challa S, Prayaga AK, Rajappa S, Ragunadhara D, et al. Primary extra nodal non Hodgkin lymphoma: A 5 year retrospective analysis. Asian Pac J Cancer Prev 2012;13:4889-95.
18. Mishra P, Das S, Kar R, Jacob SE, Basu D. Primary extranodal non-Hodgkin lymphoma: A 3-year record-based descriptive study from a tertiary care center in Southern India. Indian J PatholMicrobiol 2015;58:296-300